Oasmia Pharmaceutical AB (STO:OASM) announced on Monday that it has appointed Peter Selin as chief business officer, reporting directly to Dr Francois R. Martelet, CEO.
Selin, who has almost 20 years of business development experience, most recently serving as VP Pharma Business Operations at Inceptua Group, a pharmaceuticals company and services provider. His prior roles include appointments at Sobi, where he served as VP Corporate Development and managed partnering and licensing activities and corporate strategy projects, as well as manager, Strategy & Transformation at Ernst & Young.
Oasmia Pharmaceutical AB develops, manufactures, markets and sells an improved generation of drugs within human and veterinary oncology.
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
QST selects RayStation for advanced carbon ion therapy
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
CLS secures second order from NIH Clinical Center for Thermal Therapy System accessories